Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates

Antiviral Research

Volumn 88, Issue 1, 2010, Pages 107-115

  Chen, Weizao ^a   Xiao, Xiaodong ^a   Wang, Yanping ^a,b   Zhu, Zhongyu ^a,b   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Effector function; Engineered antibody domain; Fusion protein; Half life; HIV 1; Soluble CD4

Indexed keywords

ANTIBODY; CD4 ANTIGEN; ENGINEERED ANTIBODY DOMAIN M36; FC RECEPTOR; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HYBRID PROTEIN; IMMUNOGLOBULIN G1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY ENGINEERING; ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS NEUTRALIZATION;

ANTI-HIV AGENTS; ANTIBODY SPECIFICITY; ANTIGENS, CD4; BASE SEQUENCE; CELL ADHESION MOLECULES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77956913427     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.08.004     Document Type: Article

References (23)

1. Chen W., Zhu Z., Feng Y., Dimitrov D.S. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17121-17126.
2. Chen W., Zhu Z., Feng Y., Xiao X., Dimitrov D.S. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J. Mol. Biol. 2008, 382:779-789.
3. Chen W., Dimitrov D.S. Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr. Opin. HIV AIDS 2009, 4:112-117.
4. Chen W., Zhu Z., Feng Y., Dimitrov D.S. A large human domain antibody library combining heavy and light chain CDR3 diversity. Mol. Immunol. 2010, 47:912-921.
5. Choe H., Li W., Wright P.L., Vasilieva N., Venturi M., Huang C.C., Grundner C., Dorfman T., Zwick M.B., Wang L., Rosenberg E.S., Kwong P.D., Burton D.R., Robinson J.E., Sodroski J.G., Farzan M. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 2003, 114:161-170.
6. Choudhry V., Zhang M.Y., Dimitrova D., Prabakaran P., Dimitrov A.S., Fouts T.R., Dimitrov D.S. Antibody-based inhibitors of HIV infection. Expert Opin. Biol. Ther. 2006, 6:523-531.
7. Dey B., Del Castillo C.S., Berger E.A. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J. Virol. 2003, 77:2859-2865.
8. Forsman A., Beirnaert E., asa-Chapman M.M., Hoorelbeke B., Hijazi K., Koh W., Tack V., Szynol A., Kelly C., McKnight A., Verrips T., de H.H., Weiss R.A. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J. Virol. 2008, 82:12069-12081.
9. Fouts T.R., Tuskan R., Godfrey R., Reitz M., Hone D., Lewis G.K., DeVico A.L. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J. Virol. 2000, 74:11427-11436.
10. Hessell A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., Lanigan C.M., Landucci G., Forthal D.N., Parren P.W., Marx P.A., Burton D.R. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
11. Holt L.J., Herring C., Jespers L.S., Woolven B.P., Tomlinson I.M. Domain antibodies: proteins for therapy. Trends Biotechnol. 2003, 21:484-490.
12. Hoogenboom H.R., De Bruine A.P., Hufton S.E., Hoet R.M., Arends J.W., Roovers R.C. Antibody phage display technology and its applications. Immunotechnology 1998, 4:1-20.
13. Huang C.C., Venturi M., Majeed S., Moore M.J., Phogat S., Zhang M.Y., Dimitrov D.S., Hendrickson W.A., Robinson J., Sodroski J., Wyatt R., Choe H., Farzan M., Kwong P.D. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2706-2711.
14. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
15. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J., Vivona V., Grundner C., Huang C.C., Venturi M., Petropoulos C.J., Wrin T., Dimitrov D.S., Robinson J., Kwong P.D., Wyatt R.T., Sodroski J., Burton D.R. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 2003, 77:10557-10565.
16. Lagenaur L.A., Villarroel V.A., Bundoc V., Dey B., Berger E.A. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 2010, 7:11.
17. Moore J.P., McKeating J.A., Huang Y.X., Ashkenazi A., Ho D.D. Virons of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 1992, 66:235-243.
18. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X., Binley J.M., Zhang M.Y., Sidorov I.A., Broder C.C., Robinson J., Parren P.W., Burton D.R., Dimitrov D.S. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:6913-6918.
19. West A.P., Galimidi R.P., Foglesong C.P., Gnanapragasam P.N., Klein J.S., Bjorkman P.J. Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents. J. Virol. 2010, 84:261-269.
20. Xiang S.H., Doka N., Choudhary R.K., Sodroski J., Robinson J.E. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 2002, 18:1207-1217.
21. Xiang S.H., Wang L., Abreu M., Huang C.C., Kwong P.D., Rosenberg E., Robinson J.E., Sodroski J. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 2003, 315:124-134.
22. Zhang M.Y., Shu Y., Rudolph D., Prabakaran P., Labrijn A.F., Zwick M.B., Lal R.B., Dimitrov D.S. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J. Mol. Biol. 2004, 335:209-219.
23. Zhu Z., Dimitrov A.S., Bossart K.N., Crameri G., Bishop K.A., Choudhry V., Mungall B.A., Feng Y.R., Choudhary A., Zhang M.Y., Feng Y., Wang L.F., Xiao X., Eaton B.T., Broder C.C., Dimitrov D.S. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 2006, 80:891-899.